Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

DiaMedica Therapeutics (DMAC) Cash from Operations (2018 - 2019)

DiaMedica Therapeutics' Cash from Operations history spans 2 years, with the latest figure at 1865000.0 for Q4 2019.

For Q4 2019, Cash from Operations rose 1.84% year-over-year to 1865000.0; the TTM value through Dec 2019 reached 9102000.0, down 59.8%, while the annual FY2025 figure was 29062000.0, 31.65% down from the prior year.
Cash from Operations reached 1865000.0 in Q4 2019 per DMAC's latest filing, down from 1232000.0 in the prior quarter.
In the past five years, Cash from Operations ranged from a high of 935000.0 in Q1 2018 to a low of 3134000.0 in Q1 2019.